Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm   
Email ID
Password
Forgotten your password?
Sign me in automatically next time
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Pricing & Reimbursement
|
Regulation
|
Healthcare Policy
|
Pharmacovigilance
|
Intellectual Property
|
Policy & Regulation - Healthcare Policy
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK Promote your vacancy here
Large number of people in developing countries "impoverished" by medicines
08 September 2010
Researchers are calling for more use of generics, differential pricing by the R&D pharma industry and even compulsory licensing after a study looking at the prices of four medicines and the income levels of people living in 16 poor countries found a ...
Indian task force to back domestic growth over takeover concerns
06 September 2010
India is setting up a task force to address various policy-related, inter-ministerial and other issues in the health sector, with the aim of creating a conducive environment for the growth of the domestic pharmaceutical industry. These efforts come ...
WHO to publish global stats on H1N1 and flu vaccine usage, while pharma comes in early
07 September 2010
The World Health Organization is to publish two studies looking separately at the usage of monovalent pandemic H1N1 vaccine and the trivalent seasonal influenza jab to take stock of how these vaccines are used around the world. In the meantime, the ...
Roche mulls costs and staff cuts by year end
03 September 2010
Roche is mulling over plans to slash its operating costs to cope with "mounting pressures to curb healthcare costs" and to deal with a spate of recent setbacks in its late-stage programmes. It said it would review and analyse its organisation's ...
Activity heats up around Australian pharma pricing deal
27 August 2010
The research-based drug industry association Medicines Australia has written to a senate committee urging that the Parliament should pass before 1 October a medicines pricing bill that aims to save taxpayers Aus$1.9 billion (US$1.7 billion) over a ...
 
2010 Scrip 100 - Mixed fortunes on the R&D front
23 August 2010
Continued problems with anti-obesity drugs, more measures designed to improve R&D efficiency, and the approval of first-in-class therapeutics such as Amgen's Prolia and Dendreon's Provenge: the first ...
Liver cancer becomes more preventable and treatable
12 August 2010
New drugs to treat viral hepatitis infection, coupled with renewed interest from companies in developing therapies to treat liver cancer following Nexavar's approval, have improved prospects for both ...
2010 Scrip 100 - Changes pharma can believe in?
23 August 2010
Ian Schofield picks some of the most significant developments in the health policy and regulation circles in the first half of 2010 and explains their likely impacts on pharma. Barack Obama signed ...
 
Face-to-Face: Trophos - The French firm that hooked Actelion
23 July 2010
Actelion this week acquired the option to buy private company Trophos, with the final decision dependent on the success of the French firm's lead product olesoxime, which is in Phase III development ...
Interview: Croatia's state insurer changes its role to raise efficiency
19 July 2010
Croatia's HZZO main responsibilities include setting drug prices, selecting reimbursable products and reimbursement. The institute uses France, Italy and Slovenia as reference countries for setting ...
Connexios: Harnessing the Indian cost advantage in network biology
01 June 2010
Imagine if a start-up company could afford to hire enough high-calibre scientists to spend years creating a detailed map of a broad and complex pathology like metabolic disease, incorporating large ...
 
Value-based pricing: Who should set drug prices in the UK?
11 August 2010
While the UK's NHS and pharma sector ponder who may end up negotiating drug prices in light of a new white paper, health economists Stuart Carroll, Neil Hawkins and David A Scott contemplate four options which keep NICE very much in the picture ...
Value-based pricing for drugs: is the NHS willing to pay?
20 July 2010
Those civil servants who mill around Whitehall are quietly working on what may encompass a whole new pricing system for medicines in England following the publication of the white paper on the National Health Service (NHS) last week. The new UK ...
AstraZeneca judgement changes the rules for dominant companies
07 July 2010
On 1 July 2010 the EU General Court handed down its judgement in the long-running saga of AstraZeneca's proton pump inhibitor anti-ulcer product Losec (omeprazole). Although dealing with events that happened almost two decades ago, the case – ...
 
Polyvinylpyrrolidone–sodium hyaluronate gel (Gelclair®): a bioadherent oral gel for the treatment of oral mucositis and other painful oral lesions
01 November 2008
Background: Painful oral lesions in patients with cancer, HIV or aphthous ulcers can cause significant pain and discomfort. Those with oral mucositis (OM) resulting from high-dose chemotherapy or irradiation are the most at risk for painful lesions ...
 
COMPANY/ORGANISATION
CONDITION
GEOGRAPHY
DRUG
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm